Photo by solenfeyissa from unsplash
The availability of efficacious systemic therapies for metastatic clear cell renal cell carcinoma has heralded improved survival for Australians. The Pharmaceutical Benefits Schedule registry was interrogated to assess nation‐wide prescribing… Click to show full abstract
The availability of efficacious systemic therapies for metastatic clear cell renal cell carcinoma has heralded improved survival for Australians. The Pharmaceutical Benefits Schedule registry was interrogated to assess nation‐wide prescribing patterns. Sunitinib remained the most commonly prescribed agent. Prescribing rates were significantly lower in Northern Territory than in other states, raising questions of disparities in access to care.
Keywords:
cell carcinoma;
prescribing habits;
changes prescribing;
cell;
clear cell
Journal Title: Internal Medicine Journal
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Internal Medicine Journal
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!